Decision‐makers in Quebec are increasingly interested in the real‐world effectiveness of breakthrough palliative therapies for advanced lung cancer, like EGFR tyrosine kinase inhibitors (EGFR‐TKI). The gene discussed is EGFR; the disease is lung cancer.